# US 2025/0152576 A1 · Injectable formulation comprising isoxazoline derivative and method for preparing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152576 A1
- Document ID: US20250152576A1
- Status: Published application
- Kind: A1
- Application number: 18/839,166
- Filed: 2023-02-20
- Published: 2025-05-15
- Earliest claimed: 2022-02-23
- Assignees: LG Chem, Ltd.
- Applicants: LG Chem, Ltd.
- Inventors: Jaeuk BAEK; Sung Won KIM; Jung Woon YOON
- Web page: https://patentgrep.com/patent/US20250152576A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/4725: containing further heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 47/02: Inorganic compounds
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/02: Immunomodulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical formulation for injection comprising an isoxazoline derivative useful as a caspase inhibitor or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient (API). The pharmaceutical formulation for injection according to the present invention includes the first formulation composed of a high-dose API and the second formulation including a reconstitution solution, so that it can be prepared by mixing the first formulation and the second formulation immediately before administration to a patient, and contains the Active-API stably. Therefore, there is an advantage that effective drug efficacy can be expected when administered to a patient.

## Claims

### Claim 1

A pharmaceutical formulation for injection, comprising:
a first formulation in a powder form comprising a compound of Formula 1, a phosphate buffer, a solubilizing agent and a pH adjusting agent; and
a second formulation comprising a reconstitution solution having a pH of 5 to 12:

### Claim 2 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate.

### Claim 3 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein the phosphate buffer is contained in an amount of 1 to 15 mM based on a total volume of the first formulation.

### Claim 4 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein the solubilizing agent is cyclodextrin.

### Claim 5 (depends on 4)

The pharmaceutical formulation for injection according to claim 4, wherein the cyclodextrin is at least one selected from the group consisting of alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-beta-cyclodextrin.

### Claim 6 (depends on 4)

The pharmaceutical formulation for injection according to claim 4, wherein the cyclodextrin is contained in an amount of 10 to 30 wt % based on a total volume of the first formulation.

### Claim 7 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein a solution obtained from reconstitution by mixing the first formulation and the second formulation has a pH of 5.0 to 7.0.

### Claim 8 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein a solution obtained from reconstitution by mixing the first formulation and the second formulation has an osmotic pressure of 300 mOsm/kg to 400 mOsm/kg.

### Claim 9 (depends on 1)

The pharmaceutical formulation for injection according to claim 1, wherein a solution obtained from reconstitution by mixing the first formulation and the second formulation comprises the compound of Formula 1 in an amount of 1 to 20 mg/ml based on a total volume of the solution.

### Claim 10

A method for manufacturing a pharmaceutical formulation for injection, comprising the following steps of:
(S1) preparing a solvent having a pH of 10 to 12 including a phosphate buffer, a solubilizing agent and a basic pH adjusting agent;
(S2) preparing a first solution having a pH of 6 to 8 by dissolving the following compound of Formula 1 in the solvent prepared in (S1);
(S3) preparing a second solution having a pH of 1.0 to 3.0 by adding an acidic pH adjusting agent to the first solution;
(S4) preparing a first formulation in a powder form by freeze-drying the second solution; and
(S5) preparing a second formulation including a reconstitution solution having a pH of 5 to 12.

### Claim 11 (depends on 10)

The method for manufacturing a pharmaceutical formulation for injection according to claim 10, further comprising mixing the first formulation and the second formulation for reconstitution to prepare a solution comprising the compound of Formula 1 in an amount of 1 to 20 mg/ml based on a total volume of the solution.

### Claim 12 (depends on 10)

The method for manufacturing a pharmaceutical formulation for injection according to claim 10, wherein the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate.

### Claim 13 (depends on 10)

The method for manufacturing a pharmaceutical formulation for injection according to claim 10, wherein the phosphate buffer is contained in an amount of 1 to 15 mM based on a total volume of the solvent.

### Claim 14 (depends on 10)

The method for manufacturing a pharmaceutical formulation for injection according to claim 10, wherein the solubilizing agent is cyclodextrin.

### Claim 15 (depends on 14)

The method for manufacturing a pharmaceutical formulation for injection according to claim 14, wherein the cyclodextrin is at least one selected from the group consisting of alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-beta-cyclodextrin.

### Claim 16 (depends on 14)

The method for manufacturing a pharmaceutical formulation for injection according to claim 14, wherein the cyclodextrin is contained in an amount of 10 to 30 wt % based a total volume of the solvent.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method for administering to a subject the pharmaceutical formulation for injection according to claim 1, comprising administering a single-dose solution obtained from reconstitution by mixing the first formulation and the second formulation.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the single-dose solution of the pharmaceutical formulation for injection is administered into the joint cavity.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the single-dose solution of the pharmaceutical formulation for injection is administered into the joint cavity within 30 minutes after mixing the first formulation and the second formulation.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the single-dose solution of the pharmaceutical formulation for injection is administered once after the first formulation and the second formulation are mixed.

### Claim 23

(canceled)
